Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article
  • Published:

RETRACTED ARTICLE: Long noncoding RNA RBMS3-AS3 acts as a microRNA-4534 sponge to inhibit the progression of prostate cancer by upregulating VASH1

Gene Therapy volume 27, pages 143–156 (2020)Cite this article

Subjects

This article was retracted on 09 January 2024

This article has been updated

Abstract

Long noncoding RNAs (lncRNAs) have been demonstrated to participate in the progression of many malignancies, including prostate cancer by serving as sponges of microRNAs (miRNAs). Initial microarray-based analysis screened out the poorly expressed lncRNA RBMS3-AS3 in prostate cancer, followed by the identification of putative binding sites with miR-4534 and its target VASH1. Therefore, the present study set out to investigate the potential role of RBMS3-AS3/miR-4534/VASH1 axis in the development of prostate cancer. The biological functions of RBMS3-AS3, miR-4534, and VASH1 on cell proliferation, migration, invasion, and angiogenesis of prostate cancer were evaluated via gain- and loss-of-function experiments. Furthermore, tumor xenograft in nude mice was performed to examine tumorigenesis in vivo. The obtained results indicated that RBMS3-AS3 was poorly expressed in prostate cancer tissues and cells. Of note, overexpression of RBMS3-AS3 was found to suppress cell proliferation, migration, invasion, and angiogenesis as well as the tumorigenic ability of prostate cancer. VASH1 was verified as a target gene of miR-4534. VASH1 expression was found to be downregulated in prostate cancer tissues and cells. Interestingly, RBMS3-AS3 was observed to competitively bind to miR-4534 to upregulate VASH1 expression, resulting in a suppressive role in prostate cancer development. Also, in vitro findings were reproduced in vivo on tumor xenograft in nude mice. Taken together, the present study provides evidence suggesting that RBMS3-AS3 acts as a miR-4534 sponge to inhibit the development of prostate cancer by upregulating VASH1, highlighting a theoretical target for prostate cancer treatment.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

Similar content being viewed by others

Data availability

The datasets generated during the current study are available.

Change history

References

  1. Attard G, Parker C, Eeles RA, Schroder F, Tomlins SA, Tannock I, et al. Prostate cancer. Lancet. 2016;387:70–82.

    Article  PubMed  Google Scholar 

  2. Yedjou CG, Mbemi AT, Noubissi F, Tchounwou SS, Tsabang N, Payton M, et al. Prostate cancer disparity, chemoprevention, and treatment by specific medicinal plants. Nutrients. 2019;11: pii: E336.

  3. Lin J, Kelly WK. Targeting angiogenesis as a promising modality for the treatment of prostate cancer. Urol Clin North Am. 2012;39:547–60.

    Article  PubMed  Google Scholar 

  4. Misawa A, Takayama KI, Inoue S. Long non-coding RNAs and prostate cancer. Cancer Sci. 2017;108:2107–14.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Wang M, Zhou L, Yu F, Zhang Y, Li P, Wang K. The functional roles of exosomal long non-coding RNAs in cancer. Cell Mol Life Sci. 2019; 76:2059–76.

  6. Zhang Y, Xu Y, Feng L, Li F, Sun Z, Wu T, et al. Comprehensive characterization of lncRNA-mRNA related ceRNA network across 12 major cancers. Oncotarget. 2016;7:64148–67.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Zhang G, Han G, Zhang X, Yu Q, Li Z, Li Z, et al. Long non-coding RNA FENDRR reduces prostate cancer malignancy by competitively binding miR-18a-5p with RUNX1. Biomarkers. 2018;23:435–45.

    Article  CAS  PubMed  Google Scholar 

  8. Aghdam SG, Ebrazeh M, Hemmatzadeh M, Seyfizadeh N, Shabgah AG, Azizi G, et al. The role of microRNAs in prostate cancer migration, invasion, and metastasis. J Cell Physiol. 2019;234:9927–42.

    Article  CAS  PubMed  Google Scholar 

  9. Nip H, Dar AA, Saini S, Colden M, Varahram S, Chowdhary H, et al. Oncogenic microRNA-4534 regulates PTEN pathway in prostate cancer. Oncotarget. 2016;7:68371–84.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Kosaka T, Miyazaki Y, Miyajima A, Mikami S, Hayashi Y, Tanaka N, et al. The prognostic significance of vasohibin-1 expression in patients with prostate cancer. Br J Cancer. 2013;108:2123–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Liu S, Pan W, Cheng Z, Sun G, Zhu P, Chan F, et al. Characterization of the T-cell receptor repertoire by deep T cell receptor sequencing in tissues from patients with prostate cancer. Oncol Lett. 2018;15:1744–52.

    PubMed  Google Scholar 

  12. Lin A, Piao HL, Zhuang L, Sarbassov dos D, Ma L, Gan B. FoxO transcription factors promote AKT Ser473 phosphorylation and renal tumor growth in response to pharmacologic inhibition of the PI3K-AKT pathway. Cancer Res. 2014;74:1682–93.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.

    Article  PubMed  Google Scholar 

  14. Fernandes JCR, Acuna SM, Aoki JI, Floeter-Winter LM, Muxel SM. Long non-coding RNAs in the regulation of gene expression: physiology and disease. Noncoding RNA. 2019;5: pii: E17.

  15. Chen Q, Sun T, Wang F, Gong B, Xie W, Ma M, et al. Long noncoding RNA IGF2AS is acting as an epigenetic tumor suppressor in human prostate cancer. Urology. 2019;124:310 e1–10 e8.

    Article  PubMed  Google Scholar 

  16. Ding L, Ai D, Wu R, Zhang T, Jing L, Lu J, et al. Identification of the differential expression of serum microRNA in type 2 diabetes. Biosci Biotechnol Biochem. 2016;80:461–5.

    Article  CAS  PubMed  Google Scholar 

  17. Watanabe T, Hosaka T, Ohmori-Matsuda K, Suzuki Y, Suzuki H, Yabuki H, et al. High preoperative plasma vasohibin-1 concentration predicts better prognosis in patients with non-small cell lung carcinoma. Health Sci Rep. 2018;1:e40.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Zhou CF, Ma J, Huang L, Yi HY, Zhang YM, Wu XG, et al. Cervical squamous cell carcinoma-secreted exosomal miR-221-3p promotes lymphangiogenesis and lymphatic metastasis by targeting VASH1. Oncogene. 2019;38:1256–68.

    Article  CAS  PubMed  Google Scholar 

  19. Kosaka T, Miyazaki Y, Miyajima A, Mikami S, Hayashi Y, Tanaka N, et al. The prognostic significance of vasohibin-1 expression in patients with prostate cancer. Br J Cancer. 2013;108:2123–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Zhang T, Jing L, Li H, Ding L, Ai D, Lyu J, et al. MicroRNA-4530 promotes angiogenesis by targeting VASH1 in breast carcinoma cells. Oncol Lett. 2017;14:111–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Silva SA, Gobbo MG, Pinto-Fochi ME, Rafacho A, Taboga SR, Almeida EA, et al. Prostate hyperplasia caused by long-term obesity is characterized by high deposition of extracellular matrix and increased content of MMP-9 and VEGF. Int J Exp Pathol. 2015;96:21–30.

    Article  CAS  PubMed  Google Scholar 

  22. Chen Y, Zheng L, Liu J, Zhou Z, Cao X, Lv X, et al. Shikonin inhibits prostate cancer cells metastasis by reducing matrix metalloproteinase-2/-9 expression via AKT/mTOR and ROS/ERK1/2 pathways. Int Immunopharmacol. 2014;21:447–55.

    Article  CAS  PubMed  Google Scholar 

  23. Munoz-Moreno L, Bajo AM, Prieto JC, Carmena MJ. Growth hormone-releasing hormone (GHRH) promotes metastatic phenotypes through EGFR/HER2 transactivation in prostate cancer cells. Mol Cell Endocrinol. 2017;446:59–69.

    Article  CAS  PubMed  Google Scholar 

  24. Norita R, Suzuki Y, Furutani Y, Takahashi K, Yoshimatsu Y, Podyma-Inoue KA, et al. Vasohibin-2 is required for epithelial-mesenchymal transition of ovarian cancer cells by modulating transforming growth factor-beta signaling. Cancer Sci. 2017;108:419–26.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Kobayashi N, Uemura H, Nagahama K, Okudela K, Furuya M, Ino Y, et al. Identification of miR-30d as a novel prognostic maker of prostate cancer. Oncotarget. 2012;3:1455–71.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Li JB, Liu F, Zhang BP, Bai WK, Cheng W, Zhang YH, et al. LncRNA625 modulates prostate cancer cells proliferation and apoptosis through regulating the Wnt/beta-catenin pathway by targeting miR-432. Eur Rev Med Pharmacol Sci. 2017;21:2586–95.

    PubMed  Google Scholar 

Download references

Acknowledgements

We would like to extend our sincere appreciation to the reviewers for their helpful comments on this article.

Funding

This study was supported by Prostate Cancer Foundation China (PCF China) Young Investigator Award, National Natural Science Foundation Youth Fund (No. 81001143), Shenyang Science and Technology Program Key Science and Technology Research and Development Program (No. 17-230-9-18), the National Key Research and Development Program of China (No. 2017YFC0908003), the First Batch of Talents of Introduction of Top Health Talented Team of Qinghai Province and the First Batch of Talents of Xining “Absorbing 555 Talents Project”.

Author information

Authors and Affiliations

  1. Department of Urology, The First Hospital of China Medical University, 110001, Shenyang, PR China

    Zhenming Jiang, Yuxi Zhang & Pingeng Wu

  2. Department of Urology, People’s Hospital of Datong Hui and Tu Autonomous County, 810100, Xining, PR China

    Yuxi Zhang

  3. Department of Pharmacy, The First Hospital of China Medical University, 110001, Shenyang, PR China

    Xi Chen

  4. Central Lab, The First Hospital of China Medical University, 110001, Shenyang, PR China

    Dong Chen

Authors
  1. Zhenming Jiang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yuxi Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Xi Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Pingeng Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Dong Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Zhenming Jiang and Yuxi Zhang designed the study. Zhenming Jiang, Xi Chen, and Pingeng Wu collated the data, carried out data analyses and produced the initial draft of the manuscript. Zhenming Jiang and Dong Chen contributed to drafting the manuscript. All authors have read and approved the final submitted manuscript.

Corresponding author

Correspondence to Yuxi Zhang.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical statement

The protocols of this study were approved by the Ethic Committee of the First Hospital of China Medical University and were conducted in strict accordance with the ethical principles for medical research involving human subjects of the Helsinki Declaration. Written informed consents were obtained from all patients prior to the study. The protocol of animal experiments was approved by the Institutional Animal Care and Use Committee of the First Hospital of China Medical University. Animal experiments were conducted according to the Guide for the Care and Use of Laboratory Animals issued by the National Institutes of Health.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article has been retracted. Please see the retraction notice for more detail: https://doi.org/10.1038/s41434-023-00439-5"

Supplementary information

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Jiang, Z., Zhang, Y., Chen, X. et al. RETRACTED ARTICLE: Long noncoding RNA RBMS3-AS3 acts as a microRNA-4534 sponge to inhibit the progression of prostate cancer by upregulating VASH1. Gene Ther 27, 143–156 (2020). https://doi.org/10.1038/s41434-019-0108-1

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41434-019-0108-1

This article is cited by

Search

Advanced search

Quick links